BRIEF published on 03/23/2026 at 09:51, 5 hours ago JP Morgan Chase & Co. crosses ownership thresholds in INVENTIVA Actions Participation Threshold Crossing JP Morgan Inventiva
BRIEF published on 03/23/2026 at 09:50, 5 hours 1 minute ago Threshold crossings at INVENTIVA Shareholders Voting Rights Inventiva Threshold Crossings Shareholders' Agreement
BRIEF published on 03/16/2026 at 09:40, 7 days 5 hours ago JP Morgan Chase reduces its stake in Inventiva Actions Participation Crossing Thresholds JP Morgan Inventiva
BRIEF published on 03/12/2026 at 15:56, 10 days 22 hours ago Threshold Crossing at Inventiva Actions Stock Market Crossing Thresholds JP Morgan Chase & Co. Inventiva
BRIEF published on 02/17/2026 at 14:32, 1 month 6 days ago Threshold Crossing by Deep Track Biotechnology Voting Rights Actions Threshold Crossing Inventiva Deep Track
BRIEF published on 02/17/2026 at 08:35, 1 month 6 days ago Inventiva Reports Preliminary Financial Results for 2025 Financial Results Cash Flow Biopharmaceuticals Inventiva MASH
BRIEF published on 02/17/2026 at 08:35, 1 month 6 days ago Inventiva announces its preliminary financial results for 2025 Financial Results Treasury Biopharmaceutical Public Offering Inventiva
PRESS RELEASE published on 02/17/2026 at 08:30, 1 month 6 days ago Inventiva reports preliminary 2025¹ fiscal year financial results Inventiva reports preliminary 2025 fiscal year financial results, showing €99.3 million in cash, €131.6 million in short-term deposits, and €4.5 million in revenues Revenues Financial Results Clinical-stage Inventiva Cash Equivalents
BRIEF published on 02/04/2026 at 22:05, 1 month 18 days ago Inventiva to Participate in Guggenheim Biotech Summit 2026 Biopharmaceuticals Inventiva MASH Lanifibranor Biotech Summit
BRIEF published on 02/04/2026 at 22:05, 1 month 18 days ago Inventiva at the Guggenheim Biotech Summit 2026 New York Inventiva MASH Lanifibranor Biotech Summit
Published on 03/23/2026 at 14:05, 46 minutes ago Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Published on 03/23/2026 at 14:00, 51 minutes ago BlackBerry AtHoc Advances Command Center for Faster Response and Tighter Control During Critical Operations
Published on 03/23/2026 at 13:05, 1 hour 46 minutes ago SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Published on 03/23/2026 at 12:32, 2 hours 19 minutes ago Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 2 hours 21 minutes ago Digi Power X to Announce 2025 Year End Financial Results on March 31st
Published on 03/23/2026 at 14:30, 21 minutes ago Solvias Earns EcoVadis Bronze Medal, Ranking in Top 35% of Companies for Sustainability Performance
Published on 03/23/2026 at 14:30, 21 minutes ago Belvilla Expands in Germany with Hambachtal Holiday Park in Oberhambach
Published on 03/23/2026 at 14:24, 27 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 03/20/2026 at 19:00, 2 days 19 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 2 days 20 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 16:57, 2 days 21 hours ago Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 3 days 20 hours ago Filing of the 2025 Universal Registration Document
